US equities
|
MU
$1,035.84
▼-4.79%
NVDA
$230.48
▼-2.94%
SNDK
$1,609.46
▼-4.90%
AMD
$620.68
▼-3.90%
INTC
$107.08
▼-5.34%
AAPL
$340.42
▲+1.11%
META
$720.89
▼-0.06%
SPCX
$160.57
▼-4.19%
MU
$1,035.84
▼-4.79%
NVDA
$230.48
▼-2.94%
SNDK
$1,609.46
▼-4.90%
AMD
$620.68
▼-3.90%
INTC
$107.08
▼-5.34%
AAPL
$340.42
▲+1.11%
META
$720.89
▼-0.06%
SPCX
$160.57
▼-4.19%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Allogene Therapeutics, Inc. - Common Stock
(NQ:
ALLO
)
1.400
-0.030 (-2.10%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Allogene Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker
September 02, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Participation in September Investor Conference
August 31, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update
August 12, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update
August 04, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Cemacabtagene Ansegedleucel (Cema-Cel) as First-Line Consolidation Therapy for Large B-Cell Lymphoma
July 29, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Journal of Clinical Oncology Publication of Phase 1 Results of ALLO-316 Highlighting First Durable Remissions Following Allogeneic CAR T for Treatment of Metastatic Solid Tumors
July 15, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Planned CEO Succession
May 28, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
May 26, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update
May 13, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
May 06, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia
April 21, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026
April 20, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock
April 16, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases
April 15, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock
April 14, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Proposed Public Offering of $175 Million of Common Stock
April 13, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
ENDRA Life Sciences (NASDAQ: NDRA) Targets Billions With TAEUS® Liver Imaging Technology
April 13, 2026
Via
AB Newswire
Allogene Therapeutics Reports Interim Futility Analysis from Pivotal ALPHA3 Trial Showing 58.3% MRD Clearance with Cemacabtagene Ansegedleucel (Cema-Cel) vs. 16.7% in Observation Arm in First-Line Consolidation LBCL
April 13, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Announce Interim Futility Analysis Data from its Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First-Line Consolidation LBCL on Monday, April 13, 2026
April 10, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Update
March 12, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update
March 02, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
February 05, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff
January 12, 2026
Issued on behalf of Oncolytics Biotech Inc.
From
Equity Insider
Via
GlobeNewswire
Allogene Therapeutics Positions 2026 as a Program-Defining Year for Scalable, Real-World Allogeneic CAR T
January 08, 2026
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Reports Favorable Result for Servier in Arbitration with Cellectis
December 15, 2025
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conferences
November 10, 2025
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Reports Third Quarter 2025 Financial Results and Business Update
November 06, 2025
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
November 03, 2025
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update
October 30, 2025
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
Allogene Therapeutics Announces Participation in Upcoming Investor Conference
August 27, 2025
From
Allogene Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
Next >
